New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NZyme Pharmaceuticals(TM), Inc. Unveils New Patent for Subtilisin NAT Applications in Decreasing Blood Viscosity

Pagosa Springs, CO – July 14, 2006 – NZyme Pharmaceuticals, Inc. (d/b/a NZyme Pharm) announced today that they have a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease such as heart attacks and ischemic strokes, essential hypertension and deep vein thrombosis.

Subtilisin NAT is a pro-fibrinolytic enzyme that is present in a vegetable cheese-like food called Natto, which is extremely popular in Japan and has been consumed for over 1,000 years. Natto is prepared by fermenting boiled soybeans with Bacillus spp. (e.g., Bacillus subtilis in particular Bacillus subtilis var. natto). Traditionally, Natto was consumed as a folk remedy to treat various conditions and ailments. Subtilisin NAT may be extracted and purified from Natto.

“The new patent will be a timely arrival for the medical community as recent clinical research shows an increasing risk-to-benefit ratio with cardiovascular patients taking aspirin.” said Ralph E. Holsworth, Jr., D.O., co-founder of NZyme Pharm and director of clinical and scientific research. “With over three hundred independent cardiac risk factors, whole blood viscosity has been clinically proven to be the common denominator of vascular disease.”

NZyme brand for oral administration is provided in the form of a softchew and medical bar. All ingredients are 100% organic and non-Genetic Modified Organism (non-GMO). All prescribed medical foods contain 100 mg of Subtilisin NAT which is the fibrinolytic equivalent greater than 2,000 fibrinolytic units (FUs).

About NZyme Pharmaceuticals, Inc.

NZyme Pharmaceuticals, Inc. (NZyme Pharm) has an exclusive license to market enzymes and co-enzymes that have been clinically proven to address the etiology of disease or dysfunction. By going to the cause of the disease process and treating it on a functional basis (such as increased blood viscosity) the disease has a higher incidence of being managed or prevented. The products at NZyme Pharm re-establish fundamental cellular conditions that help people find their way back to health.

# # #

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.